Krupa Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 16-07-2024
- Paid Up Capital ₹ 0.30 M
as on 16-07-2024
- Company Age 26 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 3.50 Cr
as on 16-07-2024
- Revenue %
(FY 2023)
- Ebitda
- Net Worth
- Total Assets -0.16%
(FY 2023)
About Krupa Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.30 M.
The company has closed loans amounting to ₹3.50 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Ashok Desai, Subhashchandra Desai, and Jayendra Desai serve as directors at the Company.
- CIN/LLPIN
U24231GJ1998PTC034046
- Company No.
034046
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 May 1998
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Krupa Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ashok Desai  | Director | 01-May-1998 | Current |
| Subhashchandra Desai | Director | 01-May-1998 | Current |
| Jayendra Desai | Director | 01-May-1998 | Current |
Financial Performance of Krupa Pharmaceuticals.
Krupa Pharmaceuticals Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Krupa Pharmaceuticals?
In 2023, Krupa Pharmaceuticals had a promoter holding of 32.52% and a public holding of 67.48%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Bhavya Containers Private LimitedActive 2 years 7 monthsAshok Desai, Subhashchandra Desai and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
The Madhavpura Mercantile Co--Op. Bank Ltd. Creation Date: 12 May 1999 | ₹2.50 Cr | Satisfied |
The Madhavpura Mercantile Co--Op. Bank Ltd. Creation Date: 28 May 1998 | ₹1.00 Cr | Satisfied |
How Many Employees Work at Krupa Pharmaceuticals?
Unlock and access historical data on people associated with Krupa Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Krupa Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Krupa Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
